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Pay Now and Possibly Pay Later?*Jonathan W. Waks, MD,y Warren J. Manning, MDyzA trial ﬁbrillation (AF) is the most commonsustained arrhythmia and currently afﬂicts5 million Americans (1). The treatment of AF
and its complications costs the United States health-
care system $26 billion annually (2). Due to aging of
the population and an increasing incidence of AF
risk factors, by the year 2050, >12 million Americans
will have this arrhythmia (2). Thromboembolism and
its associated morbidity and mortality is the most
dreaded complication of AF, and AF has been impli-
cated in up to one quarter of all strokes in patients
>80 years of age (2). Anticoagulation has been shown
to reduce the risk of AF-associated stroke by 64%
and is therefore the current standard of care for
thromboembolic prophylaxis in the vast majority of
AF patients (3).
Despite the proven efﬁcacy of anticoagulation with
both warfarin and recently available non–vitamin K
oral anticoagulants, the use, safety and efﬁcacy of
chronic anticoagulation therapy is limited by bleeding
complications, medication compliance, costs, and in-
teractions with food and other medications (l).
Additionally, some patients are not candidates for
long-term anticoagulation due to a prohibitive
bleeding risk. In patients with nonvalvular AF, up to*Editorials published in the Journal of the American College of Cardiology
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Editor for this paper.91% of left atrial thrombi have been localized to the
left atrial appendage (LAA) (4,5), and the presence of
LAA thrombus, depressed LAA mechanical function,
and spontaneous echo contrast on transesophageal
echocardiogram (TEE) identify patients at increased
risk for stroke (6). As a result, LAA surgical ligation
or mechanical occlusion has emerged as a potential
alternative to oral anticoagulation to reduce the risk of
AF-related stroke without a concomitant increase in
bleeding risk.
The PROTECT AF (Watchman Left Atrial Append-
age System for Embolic Protection in Patients with
Atrial Fibrillation) randomized control trial (RCT)
compared the Watchman LAA closure (LAAC) de-
vice (Boston Scientiﬁc, Natick, Massachusetts) and
short-term warfarin followed by antiplatelet therapy
to chronic warfarin (international normalized ratio
goal 2 to 3) in 707 nonvalvular AF patients (42%
paroxysmal, 36% permanent) with at least 1 CHADS2
risk factor (mean score 2.2  1.2 with 90% hyperten-
sion and 43% $75 years of age). The Watchman was
successfully implanted in 88% of patients, and LAAC
efﬁcacy was 86% at 45 days and 92% at 6 months.
After a mean follow-up of 18 months, Watchman
LAAC was found to be non-inferior to warfarin
(time in therapeutic range 66%) for the composite
primary endpoint of stroke, systemic embolism,
and cardiovascular death (3.0 vs. 4.9 events per 100
patient-years, respectively), although there were
signiﬁcantly more adverse events (primarily peri-
procedural complications) in the Watchman group
(1.1% periprocedure stroke and 4.8% pericardial
effusion requiring percutaneous or surgical drainage)
(7). Of note, 26% of Watchman patients remained
on anticoagulation 45 days after implant, whereas
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262527% of warfarin patients interrupted warfarin during
follow-up (8). In both groups, all patients with
ischemic strokes who had international normalized
ratio measured at the time of their ischemic event
were subtherapeutic or not taking warfarin (7). Based
on these results, concerns about the risk factor pro-
ﬁles of enrolled patients, confounding by chronic
antiplatelet therapy, and poor compliance with pro-
tocol mandated anticoagulation strategies (8), the
Watchman device was not approved by the U.S.
Food and Drug Administration (FDA), and the
PREVAIL RCT was designed in concert with the FDA
to address these concerns.
The PREVAIL (Prospective Randomized Evaluation
of the Watchman LAA Closure Device In Patients With
Atrial Fibrillation Versus Long Term Warfarin Ther-
apy) trial randomized 407 nonvalvular AF patients
(50% paroxysmal, 16% permanent) with higher
CHADS2 score (mean 2.6  1.0; 91% hypertension,
54% $75 years of age), used the same Watchman
device and anticoagulation protocol as in the
PROTECT AF trial, excluded patients on chronic
clopidogrel therapy, and followed patients for a mean
of 12 months. Notably, to improve the power of the
PREVAIL study, some data from the PROTECT AF
trial was included in the PREVAIL analysis using a
Bayesian informative prior analysis. In the PREVAIL
trial, procedure-related adverse events improved to
2.2% and successful device implantation increased to
95% with LAAC efﬁcacy of 92% at 45 days and 98%
at 6 months. The Watchman failed to demonstrate
noninferiority to long-term warfarin for the compos-
ite coprimary endpoint of stroke, systemic embolism,
and cardiovascular or unexplained death. In the
Watchman group, however, at 18 months, the copri-
mary endpoint of ischemic stroke or systemic embo-
lism occurring after 7 days post-randomization was
noninferior to long-term therapy with warfarin (event
rate of 0.025 vs. 0.020, respectively). Importantly,
late ischemic stroke events in the Watchman arm
were suggested after 14 months (9).SEE PAGE 2614In this issue of the Journal, Holmes et al. (10)
present the results of a patient level meta-analysis
of the PROTECT AF and PREVAIL RCTs and their
respective registries. This meta-analysis represents
the most comprehensive and long-term evaluation of
the Watchman LAAC device to date, and includes data
on 1,877 patients treated with Watchman and 382
control patients treated with long-term warfarin,
totaling 5,931 patient-years of follow-up. The average
CHADS2 score was >2, and 90% of patients were at
a moderate to high risk of bleeding (HAS-BLED scoreof $1). Mean follow-up varied between 0.6 years in
patients enrolled in the higher CHADS2 risk PREVAIL
registry, and 4.0 years for the lower CHADS2 risk
PROTECT AF RCT patients (10).
Meta-analysis of the 2 RCTs revealed that
Watchman implantation was noninferior to long-
term warfarin for the composite outcome of stroke,
systemic embolism, and cardiovascular/unexplained
death (2.72 vs. 3.50 events per 100 patient-years,
respectively; p ¼ 0.22). There was no difference in
all-cause stroke or systemic embolism (1.75 vs. 1.87
events per 100 patient-years for Watchman and
warfarin respectively; p ¼ 0.94), or all-cause major
bleeding (p ¼ 0.95). When stroke etiology was evalu-
ated there was a borderline increase in ischemic stroke
or systemic embolism in Watchman patients (1.62
vs. 0.89 events per 100 patient-years; HR: 1.95; p ¼
0.05) with reduced hemorrhagic stroke (0.15 vs. 0.96
events per 100 patient-years; HR: 0.22; p¼ 0.004) (10).
Notably, the rate of hemorrhagic stroke in warfarin-
treated patients was nearly double the rate reported
in other contemporary AF warfarin studies (8,11,12).
When procedure-related events were excluded,
there was no difference between Watchman and
warfarin in the rate of ischemic stroke (1.4 vs. 0.89
events per 100 patient-years, respectively; p ¼ 0.21)
or major bleeding (HR: 0.51; p ¼ 0.02). The authors
also found a 52% reduction in cardiovascular death
in patients treated with Watchman compared with
warfarin (1.1 vs. 2.3 events per 100 patient-years; p ¼
0.006). Results were similar when patients in the
PROTECT AF and PREVAIL nonrandomized registries
were included in the analysis (10). These data support
the use of the Watchman as an alternative to warfarin
for thromboembolic prophylaxis in AF. However,
uncertainty remains regarding the overall safety and
late efﬁcacy of the Watchman device.
Chronic anticoagulation is associated with an
increased risk of bleeding complications, and LAAC is,
in theory, an excellent solution for reducing the risk
of LAA mediated thromboembolism in patients who
are not candidates for chronic anticoagulation. How-
ever, all patients in the PROTECT AF and PREVAIL
trials had to be eligible to take warfarin to enroll
in these studies, and all Watchman-implanted
patients were required to take warfarin for at least
45 days post-implantation (longer for the 8% to 14%
of patients without adequate LAAC), dual antiplatelet
therapy with aspirin and clopidogrel between 45 days
and 6 months after implantation (for patients with
closure), and aspirin indeﬁnitely (7,9). The safety of
the Watchman in patients who are poor candidates
for even short-term anticoagulant or antiplatelet
therapy is currently unknown. Patients with residual
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2626leakage into the LAA at 6 months may need to be on
warfarin indeﬁnitely with perhaps an increased risk
of thromboembolism (versus no Watchman) if
warfarin needs to be held/stopped. This is unfortu-
nate, as patients who are unable or unwilling to take
warfarin are the patient populations that would likely
derive the greatest beneﬁt from Watchman.
The authors refer to a small, nonrandomized trial
(Aspirin Plavix Registry) using the Watchman in 150
patients who were not eligible for long-term anti-
coagulation, which demonstrated a reasonable safety
proﬁle over short-term follow-up (13). Even these
patients, however, were treated with 6 months of
dual antiplatelet therapy and lifelong aspirin. At
this point in time, Watchman implantation with-
out peri-implant anticoagulation/antiplatelet therapy
cannot be recommended.
Data on the long-term safety of the Watchman are
also incomplete and particularly concerning. In the
original PREVAIL publication, there were similar rates
of 18-month freedom from stroke and systemic em-
bolism starting 7 days after randomization (9). With
continued follow-up, however, there were ongoing
late strokes in the Watchman group (10 of 13 total
ischemic strokes occurred after 1 year), but no new
strokes in the warfarin group. With this late increase
in Watchman-associated thromboembolic events, the
Watchman lost its non-inferiority compared to
warfarin for non-procedure related ischemic events
(event rate 0.029 vs. 0.013, respectively) (8). Of par-
ticular concern, these late ischemic strokes may be
related to late thrombus formation on the Watchman
device in the absence of anticoagulation (14).
Although LAA thrombi have been implicated in a
majority of AF-related strokes, it is important to
realize that not all strokes in AF patients are neces-
sarily related to the presence of AF and/or LAA
thrombi, and Watchman LAAC would not be ex-
pected to have any beneﬁcial effect on these types
of strokes. In 2 studies evaluating the correlation
between AF burden and thromboembolism using
implantable pacemakers and deﬁbrillators with atrial
leads to accurately and continuously record AF
burden, only 10% to 30% of patients who developed
thromboembolism had AF detected within 1 month
of their event (15,16). Patients with AF can have
ischemic strokes independent of their cardiac rhythm(e.g., from hypertension or carotid artery atheroscle-
rosis), and, in 1 study of 860 patients with AF and
stroke, 27% had a possible atheroembolic stroke eti-
ology (17). AF may also be associated with a systemic
inﬂammatory and hypercoagulable state (18). In the
current meta-analysis, w90% of patients had hyper-
tension, the most frequent stroke risk factor. Without
a method of accurately adjudicating stroke etiology,
it is possible that many strokes were unrelated to
LAA thrombi.
The Watchman has been approved in Europe
since 2005. In March 2015 it was FDA approved for use
in the United States. In a select group of patients, it
may be safe, effective, and preferable to chronic
warfarin therapy for thromboembolic prophylaxis in
AF, but at this point many questions surrounding
its safety and long-term efﬁcacy remain unanswered.
Additionally, the meta-analysis’s unusually high rate
of hemorrhagic strokes in the warfarin-treated group
may limit the beneﬁcial effect of LACC in the general
population.
As with most new technologies, over time, pro-
cedural success and safety will likely continue to
improve, and future iterations of the Watchman or
similar LAAC devices might allow safe deployment
without the need for any anticoagulant or antiplatelet
therapy. At the same time, however, pharmaceutical
approaches to AF stroke prevention are not stagnant
with the increasing use of non–vitamin K oral an-
ticoagulants demonstrating improved efﬁcacy and
lower bleeding rates vs. warfarin. This might further
reduce the beneﬁt of mechanical LAAC compared
to pharmacologic stroke prophylaxis. At this point
in time, it appears that patients treated with
Watchman may pay early (procedural complications)
and may also possibly pay later (late thromboembo-
lism). The jury is still out as we await clarity from
long-term efﬁcacy data.
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